Argatroban Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 100 mg/ mL
Reference Brands: Generic formulations marketed under different names
Category:
Critical Care
Argatroban is available in Injection
and strengths such as 100 mg/ mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Argatroban is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Argatroban can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Argatroban is an intravenous anticoagulant medication used for the prevention and treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT), a rare but potentially life-threatening immune-mediated complication associated with heparin therapy. It belongs to the class of direct thrombin inhibitors and provides effective anticoagulation without cross-reactivity with heparin antibodies.
Argatroban works by directly and reversibly inhibiting thrombin, thereby preventing fibrin formation, platelet aggregation, and clot development. It is commonly used in hospitalized and critical care settings, including during percutaneous coronary interventions in patients with HIT who require ongoing anticoagulation. Due to its rapid onset of action and short half-life, argatroban allows precise dose adjustments and close control of anticoagulant effects.
The drug is administered by continuous intravenous infusion and requires careful monitoring using activated partial thromboplastin time (aPTT). Argatroban is primarily metabolized in the liver, making it suitable for patients with renal impairment, though dose adjustments are necessary in hepatic dysfunction. Awareness of potential drug interactions, bleeding risks, and patient-specific factors is essential for safe and effective therapy. When used appropriately, argatroban remains a valuable and reliable anticoagulant option in the management of HIT.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing